Håkan Ashina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Håkan Ashina has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Messoud Ashina
Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
28 shared publications Messoud Ashina
Department of Neurology, Center for Discoveries in Migraine and Danish Headache Center, Copenhagen University Hospital – Rigshospitalet , 2600 Copenhagen
23 shared publications- Rune Häckert Christensen
Copenhagen University Hospital – Rigshospitalet
23 shared publications - Haidar Muhsen Al-Khazali
Copenhagen University Hospital – Rigshospitalet
22 shared publications Faisal Mohammad Amin
Department of Neurology, Danish Headache Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
13 shared publicationsHaidar M. Al-Khazali
Department of Neurology, Center for Discoveries in Migraine and Danish Headache Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
12 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
Atogepant for the preventive treatment of high‐frequency episodic migraine: Subgroup analysis from the ADVANCE and ELEVATE trials
Objectives/Background: High‐frequency episodic migraine (HFEM) represents a clinically important subset of episodic migraine characterized by increased disease burden, greater functional impairment, and elevated risk of migraine chronification. Atogepant is an oral calcitonin gene‐related peptide receptor antagonist approved for the preventive treatment of migraine. The objective of this analysis was to evaluate the efficacy and safety of atogepant 60 mg once daily for the preventive treatment of migraine in adults with HFEM, including in those with inadequate responses to ≥2 clasess of conventional oral non‐migraine‐specific preventive treatements. Methods: This post hoc, exploratory subgroup analysis examined participants from two 12‐week, phase 3, randomized, double‐blind, placebo‐controlled trials (ADVANCE and ELEVATE). Two subgroups were examined: the ADVANCE HFEM subgroup, which included participants from ADVANCE with 8–14 monthly migraine days (MMDs) at baseline, and the HFEM TF2+ subgroup, which comprised of pooled HFEM participants from ADVANCE and ELEVATE who had an inadequate response to ≥2 classes of conventional oral non‐migraine‐specific preventive migraine treatments. Efficacy outcomes included the change from baseline in mean MMDs, mean monthly acute medication use days, and proportion of participants achieving a ≥50%, ≥75%, or 100% reduction in mean MMDs across the 12‐week double‐blind treatment period. Functional outcomes included change from baseline in Migraine‐Specific Quality of Life Questionnaire version 2.1 Role Function‐Restrictive domain score, and Headache Impact Test‐6 total score at week 12. Safety was assessed separately for each subgroup. Results: The ADVANCE HFEM subgroup included 203 participants from the modified intent‐to‐treat population and the pooled HFEM TF2+ subgroup included 269 participants. Atogepant 60 mg once daily was associated with a greater reduction from baseline in mean MMDs compared with placebo in both the ADVANCE HFEM (least squares mean difference [LSMD] = −1.93 [95% confidence interval [CI] = −2.93 to −0.94]; nominal p < 0.001) and the pooled HFEM TF2+ subgroup (LSMD = −2.65 [95% CI = −3.60 to −1.71]; nominal p < 0.001). Reductions in mean monthly acute medication use days were similarly greater with atogepant (ADVANCE HFEM LSMD = −1.76 [95% CI = −2.58 to −0.94]; HFEM TF2+ LSMD = −2.80 [95% CI = −3.61 to −2.00]; both nominal p < 0.001). Improvements in the Migraine‐Specific Quality of Life Questionnaire version 2.1 Role Function‐Restrictive domain (ADVANCE HFEM LSMD = 9.89 [95% CI = 3.42–16.35]; HFEM TF2+ LSMD = 16.94 [95% CI = 11.93–21.96]) and Headache Impact Test‐6 total score (ADVANCE HFEM LSMD = −3.35 [95% CI = −5.46 to −1.23]; HFEM TF2+ LSMD = −5.61 [95% CI = −7.47 to −3.75]) exceeded between‐group minimally important differences (all nominal p ≤ 0.003). Safety outcomes were consistent with the full trial populations and the known safety profile of atogepant. Conclusion: In this post hoc subgroup analysis, atogepant 60 mg once daily showed greater improvements in efficacy and functional outcomes compared with placebo for the preventive treatment of HFEM, including in those with an inadequate response to ≥2 classes of conventional oral non‐migraine‐specific preventive treatments. These findings suggest atogepant represents an effective and well‐tolerated option for the preventive treatment of migraine in adults with HFEM, a population at elevated risk for chronification (NCT03777059; NCT04740827).
- 16 November 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
Open AccessAtogepant for the preventive treatment of high‐frequency episodic migraine: Subgroup analysis from the ADVANCE and ELEVATE trials
Objectives/Background: High‐frequency episodic migraine (HFEM) represents a clinically important subset of episodic migraine characterized by increased disease burden, greater functional impairment, and elevated risk of migraine chronification. Atogepant is an oral calcitonin gene‐related peptide receptor antagonist approved for the preventive treatment of migraine. The objective of this analysis was to evaluate the efficacy and safety of atogepant 60 mg once daily for the preventive treatment of migraine in adults with HFEM, including in those with inadequate responses to ≥2 clasess of conventional oral non‐migraine‐specific preventive treatements. Methods: This post hoc, exploratory subgroup analysis examined participants from two 12‐week, phase 3, randomized, double‐blind, placebo‐controlled trials (ADVANCE and ELEVATE). Two subgroups were examined: the ADVANCE HFEM subgroup, which included participants from ADVANCE with 8–14 monthly migraine days (MMDs) at baseline, and the HFEM TF2+ subgroup, which comprised of pooled HFEM participants from ADVANCE and ELEVATE who had an inadequate response to ≥2 classes of conventional oral non‐migraine‐specific preventive migraine treatments. Efficacy outcomes included the change from baseline in mean MMDs, mean monthly acute medication use days, and proportion of participants achieving a ≥50%, ≥75%, or 100% reduction in mean MMDs across the 12‐week double‐blind treatment period. Functional outcomes included change from baseline in Migraine‐Specific Quality of Life Questionnaire version 2.1 Role Function‐Restrictive domain score, and Headache Impact Test‐6 total score at week 12. Safety was assessed separately for each subgroup. Results: The ADVANCE HFEM subgroup included 203 participants from the modified intent‐to‐treat population and the pooled HFEM TF2+ subgroup included 269 participants. Atogepant 60 mg once daily was associated with a greater reduction from baseline in mean MMDs compared with placebo in both the ADVANCE HFEM (least squares mean difference [LSMD] = −1.93 [95% confidence interval [CI] = −2.93 to −0.94]; nominal p < 0.001) and the pooled HFEM TF2+ subgroup (LSMD = −2.65 [95% CI = −3.60 to −1.71]; nominal p < 0.001). Reductions in mean monthly acute medication use days were similarly greater with atogepant (ADVANCE HFEM LSMD = −1.76 [95% CI = −2.58 to −0.94]; HFEM TF2+ LSMD = −2.80 [95% CI = −3.61 to −2.00]; both nominal p < 0.001). Improvements in the Migraine‐Specific Quality of Life Questionnaire version 2.1 Role Function‐Restrictive domain (ADVANCE HFEM LSMD = 9.89 [95% CI = 3.42–16.35]; HFEM TF2+ LSMD = 16.94 [95% CI = 11.93–21.96]) and Headache Impact Test‐6 total score (ADVANCE HFEM LSMD = −3.35 [95% CI = −5.46 to −1.23]; HFEM TF2+ LSMD = −5.61 [95% CI = −7.47 to −3.75]) exceeded between‐group minimally important differences (all nominal p ≤ 0.003). Safety outcomes were consistent with the full trial populations and the known safety profile of atogepant. Conclusion: In this post hoc subgroup analysis, atogepant 60 mg once daily showed greater improvements in efficacy and functional outcomes compared with placebo for the preventive treatment of HFEM, including in those with an inadequate response to ≥2 classes of conventional oral non‐migraine‐specific preventive treatments. These findings suggest atogepant represents an effective and well‐tolerated option for the preventive treatment of migraine in adults with HFEM, a population at elevated risk for chronification (NCT03777059; NCT04740827).
- 13 November 2026
- Published by Oxford University Press (OUP) in Brain
Hypersensitivity to adrenomedullin in post-traumatic headache: a randomized crossover study
Adrenomedullin (ADM), a vasoactive member of the calcitonin peptide family with receptor-signalling overlap with calcitonin gene-related peptide (CGRP), has emerged as a candidate therapeutic target in migraine. Given the striking clinical parallels between migraine and persistent post-traumatic headache (PTH), we investigated whether ADM-responsive signalling contributes to migraine-like headache in adults with persistent PTH attributed to mild traumatic brain injury. We conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with persistent PTH and no pre-trauma history of migraine. On two experimental days separated by at least 7 days, participants received 20-minute intravenous infusions of ADM (19.9 pmol kg⁻¹ min⁻¹) and isotonic saline as the matched inactive comparator (placebo) in randomised sequence. Headache outcomes were recorded for 12 hours. The primary outcome was the within-participant incidence of experimentally induced migraine-like headache. The secondary outcome was the within-participant difference in baseline-corrected area under the curve (AUC) for headache intensity from 0 to 12 hours. Of 158 individuals assessed for eligibility, 21 were randomised, completed both periods and were analysed. Participants had a mean age of 34.3 years, 19 (90%) were female, and 18 (86%) reported a migraine-like phenotype. Migraine-like headache occurred in 17 of 21 participants (81%) after ADM and four of 21 (19%) following placebo. Fourteen participants developed migraine-like only after ADM and one only following placebo, yielding a paired absolute risk difference of 61.9 percentage points (95% CI 29.7–80.6; one-sided P < 0.001; two-sided P = 0.001). Baseline-corrected headache-intensity AUC was higher after ADM than placebo (median 1,110 [IQR 315–2205] versus 420 [−160 to 565]; P = 0.006). Median time to onset of migraine-like headache was 30 minutes after ADM and 390 minutes following placebo. Fifteen participants reported that the ADM-induced headache resembled their usual migraine-like headache episodes, and rescue medication was used by 10 participants after ADM and two after placebo. These findings identify pronounced responsiveness to ADM-linked signalling in persistent PTH and support the ADM pathway as a candidate target for mechanism-based therapeutic development, pending confirmation in independent cohorts and complementary preclinical studies.
- 13 November 2026
- Published by Oxford University Press (OUP) in Brain
Hypersensitivity to adrenomedullin in post-traumatic headache: a randomized crossover study
Adrenomedullin (ADM), a vasoactive member of the calcitonin peptide family with receptor-signalling overlap with calcitonin gene-related peptide (CGRP), has emerged as a candidate therapeutic target in migraine. Given the striking clinical parallels between migraine and persistent post-traumatic headache (PTH), we investigated whether ADM-responsive signalling contributes to migraine-like headache in adults with persistent PTH attributed to mild traumatic brain injury. We conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with persistent PTH and no pre-trauma history of migraine. On two experimental days separated by at least 7 days, participants received 20-minute intravenous infusions of ADM (19.9 pmol kg⁻¹ min⁻¹) and isotonic saline as the matched inactive comparator (placebo) in randomised sequence. Headache outcomes were recorded for 12 hours. The primary outcome was the within-participant incidence of experimentally induced migraine-like headache. The secondary outcome was the within-participant difference in baseline-corrected area under the curve (AUC) for headache intensity from 0 to 12 hours. Of 158 individuals assessed for eligibility, 21 were randomised, completed both periods and were analysed. Participants had a mean age of 34.3 years, 19 (90%) were female, and 18 (86%) reported a migraine-like phenotype. Migraine-like headache occurred in 17 of 21 participants (81%) after ADM and four of 21 (19%) following placebo. Fourteen participants developed migraine-like only after ADM and one only following placebo, yielding a paired absolute risk difference of 61.9 percentage points (95% CI 29.7–80.6; one-sided P < 0.001; two-sided P = 0.001). Baseline-corrected headache-intensity AUC was higher after ADM than placebo (median 1,110 [IQR 315–2205] versus 420 [−160 to 565]; P = 0.006). Median time to onset of migraine-like headache was 30 minutes after ADM and 390 minutes following placebo. Fifteen participants reported that the ADM-induced headache resembled their usual migraine-like headache episodes, and rescue medication was used by 10 participants after ADM and two after placebo. These findings identify pronounced responsiveness to ADM-linked signalling in persistent PTH and support the ADM pathway as a candidate target for mechanism-based therapeutic development, pending confirmation in independent cohorts and complementary preclinical studies.
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in Brain Communications
Plasma adrenomedullin and response to erenumab in migraine: a REFORM study
Adrenomedullin has been implicated in migraine pathogenesis and is structurally related to calcitonin gene–related peptide. However, it remains unknown whether circulating adrenomedullin reflects migraine biology or identifies patients most likely to benefit from calcitonin gene–related peptide-receptor blockade. We examined whether plasma adrenomedullin levels predict or reflect the clinical effects of erenumab for migraine prevention. In this prospective, single-centre biomarker study within the Registry for Migraine program, adults with episodic or chronic migraine received erenumab 140 mg every 4 weeks for 24 weeks, followed by 24 weeks of post-treatment follow-up. Plasma adrenomedullin concentrations were measured at baseline, Week 24, and Week 48 using a validated immunoluminometric assay. Co-primary outcomes were the association between baseline plasma adrenomedullin and either a ≥50% reduction in monthly migraine days or the absolute change in monthly migraine days from baseline to Weeks 13–24. Secondary analyses compared plasma adrenomedullin across responders, non-responders, and healthy controls and assessed longitudinal changes. A total of 632 participants with migraine (mean age 44.1 ± 12.3 years; 90.2% female; 61.2% chronic migraine) contributed at least one plasma sample, and 147 healthy controls were included as a matched reference group. Among 539 participants with evaluable response data, 276 (51.2%) were responders. Baseline plasma adrenomedullin was not associated with a ≥50% reduction in monthly migraine days (OR, 1.00; 95% CI, 0.99 to 1.03; P = 0.60) or absolute monthly migraine days reduction (β, 0.052 days per pg/mL; 95% CI, −0.002 to 0.106; P = 0.06). Plasma adrenomedullin concentrations did not differ between responders and non-responders at any time point and were similar between participants with migraine and healthy controls. Concentrations remained stable during treatment and were not correlated with changes in headache frequency or severity. Sensitivity analyses confirmed the primary findings. Plasma adrenomedullin neither predicted nor reflected clinical response to erenumab in adults with migraine. These findings suggest that circulating adrenomedullin is unlikely to serve as a clinically useful biomarker for treatment selection or disease monitoring in migraine.
- 10 November 2026
- Published by Oxford University Press (OUP) in Brain Communications
Open AccessPlasma adrenomedullin and response to erenumab in migraine: a REFORM study
Adrenomedullin has been implicated in migraine pathogenesis and is structurally related to calcitonin gene–related peptide. However, it remains unknown whether circulating adrenomedullin reflects migraine biology or identifies patients most likely to benefit from calcitonin gene–related peptide-receptor blockade. We examined whether plasma adrenomedullin levels predict or reflect the clinical effects of erenumab for migraine prevention. In this prospective, single-centre biomarker study within the Registry for Migraine program, adults with episodic or chronic migraine received erenumab 140 mg every 4 weeks for 24 weeks, followed by 24 weeks of post-treatment follow-up. Plasma adrenomedullin concentrations were measured at baseline, Week 24, and Week 48 using a validated immunoluminometric assay. Co-primary outcomes were the association between baseline plasma adrenomedullin and either a ≥50% reduction in monthly migraine days or the absolute change in monthly migraine days from baseline to Weeks 13–24. Secondary analyses compared plasma adrenomedullin across responders, non-responders, and healthy controls and assessed longitudinal changes. A total of 632 participants with migraine (mean age 44.1 ± 12.3 years; 90.2% female; 61.2% chronic migraine) contributed at least one plasma sample, and 147 healthy controls were included as a matched reference group. Among 539 participants with evaluable response data, 276 (51.2%) were responders. Baseline plasma adrenomedullin was not associated with a ≥50% reduction in monthly migraine days (OR, 1.00; 95% CI, 0.99 to 1.03; P = 0.60) or absolute monthly migraine days reduction (β, 0.052 days per pg/mL; 95% CI, −0.002 to 0.106; P = 0.06). Plasma adrenomedullin concentrations did not differ between responders and non-responders at any time point and were similar between participants with migraine and healthy controls. Concentrations remained stable during treatment and were not correlated with changes in headache frequency or severity. Sensitivity analyses confirmed the primary findings. Plasma adrenomedullin neither predicted nor reflected clinical response to erenumab in adults with migraine. These findings suggest that circulating adrenomedullin is unlikely to serve as a clinically useful biomarker for treatment selection or disease monitoring in migraine.
- Open Access
- 13 October 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
Plasma amylin levels in migraine and after erenumab treatment: A REFORM study
Objective: To investigate whether plasma amylin concentrations differ between adults with migraine and healthy controls (HCs) and whether baseline or longitudinal amylin levels are associated with treatment response to erenumab. Background: Amylin is a calcitonin family peptide closely related to calcitonin gene–related peptide, with overlapping receptor pharmacology, and has been implicated in migraine. Human provocation studies have shown that pramlintide, an amylin analogue, triggers migraine attacks, but it remains unclear whether plasma amylin distinguishes people with migraine from HCs, varies across migraine subtypes, predicts response to erenumab, or changes during treatment. Methods: This prospective longitudinal analysis was conducted within the Registry for Migraine study at the Danish Headache Center (Copenhagen, Denmark). Adults with migraine (≥4 monthly migraine days) and age‐ and sex‐similar HCs were enrolled between September 2020 and June 2022. Plasma samples were collected under standardized conditions at baseline and after 24 weeks of erenumab treatment (140 mg every 4 weeks). Treatment response was defined as a ≥50% reduction in monthly migraine days during weeks 13 to 24 compared with baseline. Plasma amylin was quantified from November 2023 to March 2024 using a competitive immunoassay that was selected after head‐to‐head kit validation, which included assessment of parallelism and spike recovery with human plasma. Results: A total of 121 adults with migraine and 63 HCs were enrolled; 100 participants with migraine completed 24 weeks of erenumab treatment and provided evaluable efficacy data. At baseline, plasma amylin concentrations were not significantly different between erenumab responders ( n = 55) and nonresponders ( n = 45) (9.0 ± 2.3 vs. 8.6 ± 1.7 ng/mL; p > 0.999), and concentrations of both groups were not statistically significantly different from HCs (9.2 ± 1.7 ng/mL; p > 0.999 and p = 0.220, respectively). At 24 weeks, plasma amylin concentrations did not differ significantly between responders and nonresponders (8.8 ± 2.2 vs. 8.3 ± 2.1 ng/mL; p = 0.676). In paired analyses ( n = 100), plasma amylin levels did not change from baseline to week 24 ( p = 0.208). Baseline plasma amylin concentrations did not differ across migraine subgroups (episodic vs. chronic, with aura vs. without aura, ictal vs. interictal) and were not associated with key clinical variables. Conclusion: Plasma amylin levels did not differ between adults with migraine and HCs, across clinically relevant migraine subgroups, or by response to erenumab. These findings do not support plasma amylin as a clinically useful disease or treatment‐response biomarker and are consistent with the broader concept that migraine‐relevant peptidergic signaling may be compartmentalized and not captured by peripheral venous blood sampling. image
- 13 October 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
Open AccessPlasma amylin levels in migraine and after erenumab treatment: A REFORM study
Objective: To investigate whether plasma amylin concentrations differ between adults with migraine and healthy controls (HCs) and whether baseline or longitudinal amylin levels are associated with treatment response to erenumab. Background: Amylin is a calcitonin family peptide closely related to calcitonin gene–related peptide, with overlapping receptor pharmacology, and has been implicated in migraine. Human provocation studies have shown that pramlintide, an amylin analogue, triggers migraine attacks, but it remains unclear whether plasma amylin distinguishes people with migraine from HCs, varies across migraine subtypes, predicts response to erenumab, or changes during treatment. Methods: This prospective longitudinal analysis was conducted within the Registry for Migraine study at the Danish Headache Center (Copenhagen, Denmark). Adults with migraine (≥4 monthly migraine days) and age‐ and sex‐similar HCs were enrolled between September 2020 and June 2022. Plasma samples were collected under standardized conditions at baseline and after 24 weeks of erenumab treatment (140 mg every 4 weeks). Treatment response was defined as a ≥50% reduction in monthly migraine days during weeks 13 to 24 compared with baseline. Plasma amylin was quantified from November 2023 to March 2024 using a competitive immunoassay that was selected after head‐to‐head kit validation, which included assessment of parallelism and spike recovery with human plasma. Results: A total of 121 adults with migraine and 63 HCs were enrolled; 100 participants with migraine completed 24 weeks of erenumab treatment and provided evaluable efficacy data. At baseline, plasma amylin concentrations were not significantly different between erenumab responders ( n = 55) and nonresponders ( n = 45) (9.0 ± 2.3 vs. 8.6 ± 1.7 ng/mL; p > 0.999), and concentrations of both groups were not statistically significantly different from HCs (9.2 ± 1.7 ng/mL; p > 0.999 and p = 0.220, respectively). At 24 weeks, plasma amylin concentrations did not differ significantly between responders and nonresponders (8.8 ± 2.2 vs. 8.3 ± 2.1 ng/mL; p = 0.676). In paired analyses ( n = 100), plasma amylin levels did not change from baseline to week 24 ( p = 0.208). Baseline plasma amylin concentrations did not differ across migraine subgroups (episodic vs. chronic, with aura vs. without aura, ictal vs. interictal) and were not associated with key clinical variables. Conclusion: Plasma amylin levels did not differ between adults with migraine and HCs, across clinically relevant migraine subgroups, or by response to erenumab. These findings do not support plasma amylin as a clinically useful disease or treatment‐response biomarker and are consistent with the broader concept that migraine‐relevant peptidergic signaling may be compartmentalized and not captured by peripheral venous blood sampling. image
- Open Access
- 5 October 2026
- Published by Springer Nature in The Journal of Headache and Pain
Triggering migraine attacks using PACAP: a systematic review of human provocation studies
- 5 October 2026
- Published by Springer Nature in The Journal of Headache and Pain
Open AccessTriggering migraine attacks using PACAP: a systematic review of human provocation studies
- Open Access
- 11 August 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (8)
Blood levels of PACAP in migraine: A systematic review
Objective: To examine whether plasma or serum pituitary adenylate cyclase-activating polypeptide (PACAP) levels differ between people with migraine and healthy controls (HCs), and to assess evidence for dynamic alterations during migraine attacks. Methods: A systematic literature search was conducted in PubMed and Embase from inception to December 19, 2025. Eligible studies measured PACAP in plasma or serum of adult or pediatric participants with migraine and reported comparisons with HCs, and/or between ictal and interictal phases. Two reviewers independently screened articles, extracted data, and assessed risk of bias using the QUADAS-2 tool. Results: Eleven studies met the inclusion criteria, comprising seven adult and four pediatric studies. Findings were inconsistent across studies, with some reporting higher PACAP-38 levels in participants with migraine, while others found no differences or even lower levels compared with HCs. Five studies compared ictal and interictal levels, but results were incongruent and lacked intraindividual measurements. Furthermore, all studies were judged to be at high overall risk of bias, primarily due to limitations in participant selection and index test methodology. Conclusions: Current evidence on plasma or serum PACAP-38 levels in migraine is limited and inconsistent. The lack of intraindividual ictal-interictal comparisons and variability in study design and assays further weaken conclusions. Standardized, high-quality studies are essential to resolve existing uncertainties. Trial Registration: The study protocol was prospectively registered in PROSPERO (CRD42024601373).
- 11 August 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (8)
Open AccessBlood levels of PACAP in migraine: A systematic review
Objective: To examine whether plasma or serum pituitary adenylate cyclase-activating polypeptide (PACAP) levels differ between people with migraine and healthy controls (HCs), and to assess evidence for dynamic alterations during migraine attacks. Methods: A systematic literature search was conducted in PubMed and Embase from inception to December 19, 2025. Eligible studies measured PACAP in plasma or serum of adult or pediatric participants with migraine and reported comparisons with HCs, and/or between ictal and interictal phases. Two reviewers independently screened articles, extracted data, and assessed risk of bias using the QUADAS-2 tool. Results: Eleven studies met the inclusion criteria, comprising seven adult and four pediatric studies. Findings were inconsistent across studies, with some reporting higher PACAP-38 levels in participants with migraine, while others found no differences or even lower levels compared with HCs. Five studies compared ictal and interictal levels, but results were incongruent and lacked intraindividual measurements. Furthermore, all studies were judged to be at high overall risk of bias, primarily due to limitations in participant selection and index test methodology. Conclusions: Current evidence on plasma or serum PACAP-38 levels in migraine is limited and inconsistent. The lack of intraindividual ictal-interictal comparisons and variability in study design and assays further weaken conclusions. Standardized, high-quality studies are essential to resolve existing uncertainties. Trial Registration: The study protocol was prospectively registered in PROSPERO (CRD42024601373).
- Open Access
- 24 July 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (7) , e70714
Association of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study
Background: Experimental studies show inflammatory cytokines can modulate calcitonin gene‐related peptide (CGRP) signaling, suggesting systemic inflammatory markers might reflect biological processes relevant to anti‐CGRP therapies. We aimed to determine whether serum high‐sensitivity C‐reactive protein (hs‐CRP) and tumor necrosis factor‐alpha (TNF‐α) are associated with erenumab response in adults with migraine and assess longitudinal biomarker changes during and after treatment. Methods: In this prospective, observational single‐center study, adults with episodic or chronic migraine self‐administered 140 mg erenumab subcutaneously every 4 weeks for 24 weeks. Serum was collected at baseline, Week 24 (end of treatment), and Week 48 (24 weeks post‐treatment). Treatment response was defined as a ≥ 50% reduction in monthly migraine days from baseline to Weeks 13–24. Logistic and linear regression models evaluated associations between baseline biomarkers and response, while longitudinal changes were analyzed using linear mixed‐effects models. Results: Of 679 enrolled participants, serum was analyzed in 623. Among 541 with sufficient data to determine response, 281 (51.9%) were responders. Neither baseline hs‐CRP (OR 1.04; 95% CI 0.96–1.12; p = 0.30) nor TNF‐α (OR 0.75; 95% CI 0.49–1.16; p = 0.20) predicted treatment response. TNF‐α increased from baseline to Week 24 (mean rise 3.0%; 95% CI 0.5%–5.4%; p = 0.030), but no responder–non‐responder differences were found. Conclusions: Peripheral inflammatory biomarkers such as hs‐CRP and TNF‐α neither predict response nor change meaningfully during CGRP‐receptor blockade. These results suggest broadly applied inflammatory markers do not capture treatment‐relevant biology and highlight the need for mechanism‐specific biomarkers to advance personalized migraine therapy.
- 24 July 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (7) , e70714
Open AccessAssociation of Serum hs‐ CRP and TNF ‐α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine ( REFORM ) Study
Background: Experimental studies show inflammatory cytokines can modulate calcitonin gene‐related peptide (CGRP) signaling, suggesting systemic inflammatory markers might reflect biological processes relevant to anti‐CGRP therapies. We aimed to determine whether serum high‐sensitivity C‐reactive protein (hs‐CRP) and tumor necrosis factor‐alpha (TNF‐α) are associated with erenumab response in adults with migraine and assess longitudinal biomarker changes during and after treatment. Methods: In this prospective, observational single‐center study, adults with episodic or chronic migraine self‐administered 140 mg erenumab subcutaneously every 4 weeks for 24 weeks. Serum was collected at baseline, Week 24 (end of treatment), and Week 48 (24 weeks post‐treatment). Treatment response was defined as a ≥ 50% reduction in monthly migraine days from baseline to Weeks 13–24. Logistic and linear regression models evaluated associations between baseline biomarkers and response, while longitudinal changes were analyzed using linear mixed‐effects models. Results: Of 679 enrolled participants, serum was analyzed in 623. Among 541 with sufficient data to determine response, 281 (51.9%) were responders. Neither baseline hs‐CRP (OR 1.04; 95% CI 0.96–1.12; p = 0.30) nor TNF‐α (OR 0.75; 95% CI 0.49–1.16; p = 0.20) predicted treatment response. TNF‐α increased from baseline to Week 24 (mean rise 3.0%; 95% CI 0.5%–5.4%; p = 0.030), but no responder–non‐responder differences were found. Conclusions: Peripheral inflammatory biomarkers such as hs‐CRP and TNF‐α neither predict response nor change meaningfully during CGRP‐receptor blockade. These results suggest broadly applied inflammatory markers do not capture treatment‐relevant biology and highlight the need for mechanism‐specific biomarkers to advance personalized migraine therapy.
- Top Cited PapersOpen Access
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218152
Plasma CGRP Levels in Migraine
Calcitonin gene-related peptide (CGRP) plays a central mechanistic role in migraine and is an established drug target. However, it remains unclear whether peripheral plasma CGRP levels meaningfully reflect disease activity. We investigated whether circulating plasma CGRP differs between individuals with migraine and healthy controls and whether concentrations vary across migraine subtypes, clinical status, and preventive treatment use. This cross-sectional observational study enrolled adults (≥18 years) with migraine with aura, migraine without aura, or chronic migraine primarily from specialized care. Healthy controls without personal or first-degree family history of primary headache disorders were mainly recruited through web-based advertisement. Venous blood was obtained by antecubital phlebotomy, and plasma CGRP was quantified in duplicate using a validated high-affinity radioimmunoassay. Controls were matched 1:4 to participants with migraine on age, sex, body mass index, and storage duration. The primary outcome was between-group difference in plasma CGRP concentrations. Group comparisons were performed using Mann-Whitney U tests. Regression models were performed to assess associations with clinical variables. A total of 588 participants with migraine and 147 matched controls were analyzed (mean age 43.1 ± 11.9 vs 41.5 ± 11.5 years; 88.8% vs 85.7% female). The median (interquartile range) plasma CGRP concentrations were lower in participants with migraine compared with controls (125 [68-173] vs 151 [118-199] pmol/L; p < 0.001). Subgroup analyses revealed no significant differences across subtypes (episodic vs chronic, with aura vs without aura), ictal vs interictal status, or preventive medication use (all p > 0.05). Sensitivity analyses restricted to headache-free participants confirmed the principal findings, demonstrating lower plasma CGRP concentrations across all migraine subgroups compared with controls (all p < 0.001). Multivariable models identified no clinical predictors of plasma CGRP levels. Sample storage duration did not correlate with measured levels (Spearman ρ = -0.032; p = 0.37). Plasma CGRP concentrations were modestly lower in migraine and did not vary by clinical subtype or disease state. These findings challenge the assumption that migraine is characterized by elevated circulating CGRP and suggest limited utility of plasma CGRP as a disease biomarker.
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218152
Top Cited PapersOpen AccessPlasma CGRP Levels in Migraine
Calcitonin gene-related peptide (CGRP) plays a central mechanistic role in migraine and is an established drug target. However, it remains unclear whether peripheral plasma CGRP levels meaningfully reflect disease activity. We investigated whether circulating plasma CGRP differs between individuals with migraine and healthy controls and whether concentrations vary across migraine subtypes, clinical status, and preventive treatment use. This cross-sectional observational study enrolled adults (≥18 years) with migraine with aura, migraine without aura, or chronic migraine primarily from specialized care. Healthy controls without personal or first-degree family history of primary headache disorders were mainly recruited through web-based advertisement. Venous blood was obtained by antecubital phlebotomy, and plasma CGRP was quantified in duplicate using a validated high-affinity radioimmunoassay. Controls were matched 1:4 to participants with migraine on age, sex, body mass index, and storage duration. The primary outcome was between-group difference in plasma CGRP concentrations. Group comparisons were performed using Mann-Whitney U tests. Regression models were performed to assess associations with clinical variables. A total of 588 participants with migraine and 147 matched controls were analyzed (mean age 43.1 ± 11.9 vs 41.5 ± 11.5 years; 88.8% vs 85.7% female). The median (interquartile range) plasma CGRP concentrations were lower in participants with migraine compared with controls (125 [68-173] vs 151 [118-199] pmol/L; p < 0.001). Subgroup analyses revealed no significant differences across subtypes (episodic vs chronic, with aura vs without aura), ictal vs interictal status, or preventive medication use (all p > 0.05). Sensitivity analyses restricted to headache-free participants confirmed the principal findings, demonstrating lower plasma CGRP concentrations across all migraine subgroups compared with controls (all p < 0.001). Multivariable models identified no clinical predictors of plasma CGRP levels. Sample storage duration did not correlate with measured levels (Spearman ρ = -0.032; p = 0.37). Plasma CGRP concentrations were modestly lower in migraine and did not vary by clinical subtype or disease state. These findings challenge the assumption that migraine is characterized by elevated circulating CGRP and suggest limited utility of plasma CGRP as a disease biomarker.
- Open Access
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis
To determine the efficacy and tolerability of a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks in adults. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines, with the protocol prospectively registered in PROSPERO (Identifier: CRD420251042015). Comprehensive searches of CENTRAL, ClinicalTrials.gov, EMBASE, EUCTR, PubMed, and WHO ICTRP were performed from database inception to December 2025, without language restrictions. Supplementary sources were also reviewed, including regulatory and sponsor materials such as FDA and EMA submissions and entries in the Pfizer and Biohaven clinical trial registries. Eligible studies were double-blind randomized controlled trials enrolling adults (≥ 18 years) with migraine (with or without aura) who received a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks. The co-primary outcomes were pain freedom at 2 h post-dose and sustained pain freedom from 2 to 24 h post-dose. Tolerability outcomes included all non-serious adverse events (AEs) following dosing, whereas safety outcomes comprised serious adverse events. Risk of bias was evaluated using the Cochrane RoB 2 tool, and certainty of evidence was assessed using the GRADE framework. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, and heterogeneity was quantified using the I² and τ² statistics. Seven double-blind RCTs (one phase II, five phase III, one phase IV) comprising 6,734 participants met the inclusion criteria. Two hours post-dose, 19.8% of participants receiving rimegepant and 10.7% receiving placebo achieved pain freedom (RR, 1.93; 95% CI, 1.51-2.47; P < 0.001; NNT = 10). Sustained pain freedom from 2 to 24 h was achieved by 14.2% of those receiving rimegepant, compared with 6.3% receiving placebo (RR, 2.39; 95% CI, 1.75-3.27; P < 0.001; NNT = 11). AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30; P = 0.056; NNH = 55). Risk of bias was judged as low across the included trials. Rimegepant 75 mg provides modest yet clinically meaningful efficacy with favorable short-term tolerability for the acute treatment of migraine attacks. These findings support its use as an effective treatment option for adults with inadequate response, contraindications, or intolerance to first- or second-line therapies. Not applicable.
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessRimegepant for the acute treatment of migraine: a systematic review and meta-analysis
To determine the efficacy and tolerability of a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks in adults. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines, with the protocol prospectively registered in PROSPERO (Identifier: CRD420251042015). Comprehensive searches of CENTRAL, ClinicalTrials.gov, EMBASE, EUCTR, PubMed, and WHO ICTRP were performed from database inception to December 2025, without language restrictions. Supplementary sources were also reviewed, including regulatory and sponsor materials such as FDA and EMA submissions and entries in the Pfizer and Biohaven clinical trial registries. Eligible studies were double-blind randomized controlled trials enrolling adults (≥ 18 years) with migraine (with or without aura) who received a single 75 mg oral dose of rimegepant compared with placebo for the acute treatment of migraine attacks. The co-primary outcomes were pain freedom at 2 h post-dose and sustained pain freedom from 2 to 24 h post-dose. Tolerability outcomes included all non-serious adverse events (AEs) following dosing, whereas safety outcomes comprised serious adverse events. Risk of bias was evaluated using the Cochrane RoB 2 tool, and certainty of evidence was assessed using the GRADE framework. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, and heterogeneity was quantified using the I² and τ² statistics. Seven double-blind RCTs (one phase II, five phase III, one phase IV) comprising 6,734 participants met the inclusion criteria. Two hours post-dose, 19.8% of participants receiving rimegepant and 10.7% receiving placebo achieved pain freedom (RR, 1.93; 95% CI, 1.51-2.47; P < 0.001; NNT = 10). Sustained pain freedom from 2 to 24 h was achieved by 14.2% of those receiving rimegepant, compared with 6.3% receiving placebo (RR, 2.39; 95% CI, 1.75-3.27; P < 0.001; NNT = 11). AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30; P = 0.056; NNH = 55). Risk of bias was judged as low across the included trials. Rimegepant 75 mg provides modest yet clinically meaningful efficacy with favorable short-term tolerability for the acute treatment of migraine attacks. These findings support its use as an effective treatment option for adults with inadequate response, contraindications, or intolerance to first- or second-line therapies. Not applicable.
- Open Access
- 14 May 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (5)
Magnetic resonance spectroscopy during migraine attacks: A systematic review
Background: The neurobiological basis of migraine remains incompletely understood. Magnetic resonance spectroscopy (MRS) allows non-invasive quantification of neurochemical and metabolic patterns in the brain, offering unique insights into biochemical processes during distinct migraine phases. This systematic review provides a critical appraisal of existing evidence describing MRS-derived neurochemical and metabolic alterations during spontaneous and experimentally provoked migraine attacks. Methods: A systematic review was conducted in accordance with the PRISMA statement and prospectively registered in PROSPERO. Comprehensive searches of PubMed, Embase, and Scopus were performed from database inception through August 1, 2025. Eligible studies included observational or interventional investigations acquiring 1 H-MRS or 31 P-MRS data during the ictal phase in adults with migraine, incorporating either non-ictal comparisons or healthy controls. Considerable variability in study design, brain regions, and metabolite outcomes precluded quantitative synthesis, necessitating a structured qualitative analysis organized by MRS technique and anatomical region. Results: Eight studies published between 1988 and 2022 met inclusion criteria, comprising five 1 H-MRS investigations and three 31 P-MRS studies, some of which derived from overlapping participant cohorts. Brain regions examined included occipital cortex, pons, frontal cortex, basal ganglia, and parieto-occipital areas. In individual 1 H-MRS studies, occipital cortex analyses demonstrated ictal elevations in total choline and total N-acetyl aspartate, while lower glutathione concentrations were observed. A single 1 H-MRS study targeting the pons identified ictal increases in total creatine and total N-acetyl aspartate. Findings from 31 P-MRS studies indicated altered cerebral energy metabolism during migraine attacks. Conclusions: Available MRS evidence suggests that migraine attacks are associated with altered cerebral energy metabolism, particularly within visual cortical and brainstem regions. However, existing studies differ substantially in design, acquisition parameters, regions of interest, and analytical approaches, such that few directly address comparable questions. Thus, the reproducibility of reported findings remains uncertain. Establishing reliable attack-related metabolic signatures will require well-designed longitudinal MRS investigations capable of directly probing ictal dynamics.
- 14 May 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (5)
Open AccessMagnetic resonance spectroscopy during migraine attacks: A systematic review
Background: The neurobiological basis of migraine remains incompletely understood. Magnetic resonance spectroscopy (MRS) allows non-invasive quantification of neurochemical and metabolic patterns in the brain, offering unique insights into biochemical processes during distinct migraine phases. This systematic review provides a critical appraisal of existing evidence describing MRS-derived neurochemical and metabolic alterations during spontaneous and experimentally provoked migraine attacks. Methods: A systematic review was conducted in accordance with the PRISMA statement and prospectively registered in PROSPERO. Comprehensive searches of PubMed, Embase, and Scopus were performed from database inception through August 1, 2025. Eligible studies included observational or interventional investigations acquiring 1 H-MRS or 31 P-MRS data during the ictal phase in adults with migraine, incorporating either non-ictal comparisons or healthy controls. Considerable variability in study design, brain regions, and metabolite outcomes precluded quantitative synthesis, necessitating a structured qualitative analysis organized by MRS technique and anatomical region. Results: Eight studies published between 1988 and 2022 met inclusion criteria, comprising five 1 H-MRS investigations and three 31 P-MRS studies, some of which derived from overlapping participant cohorts. Brain regions examined included occipital cortex, pons, frontal cortex, basal ganglia, and parieto-occipital areas. In individual 1 H-MRS studies, occipital cortex analyses demonstrated ictal elevations in total choline and total N-acetyl aspartate, while lower glutathione concentrations were observed. A single 1 H-MRS study targeting the pons identified ictal increases in total creatine and total N-acetyl aspartate. Findings from 31 P-MRS studies indicated altered cerebral energy metabolism during migraine attacks. Conclusions: Available MRS evidence suggests that migraine attacks are associated with altered cerebral energy metabolism, particularly within visual cortical and brainstem regions. However, existing studies differ substantially in design, acquisition parameters, regions of interest, and analytical approaches, such that few directly address comparable questions. Thus, the reproducibility of reported findings remains uncertain. Establishing reliable attack-related metabolic signatures will require well-designed longitudinal MRS investigations capable of directly probing ictal dynamics.